

## Colorado Consortium for Prescription Drug Abuse Prevention

### PDMP Work Group Meeting Minutes

July 8, 2021 via Zoom

**Present:**

Jason Hoppe, DO (Co-chair)  
Dmitry Kunin, DORA, (Co-chair)  
Aminta Bhutani, DEA  
Carrie Paykoc, Governor's Office  
Nagy Ramzy, Pharmacist  
Marjorie Zimdars-Orthman, Community Member  
Krista Batchelder, Attorney General's Office  
CDPHE: Barbara Gabella, Katie Sullivan, Andres Guerrero, Anne Milliken  
Consortium: Rob Valuck, Gina Olberding, Jessica Eaddy, Tyler Payne, Jamie Feld, Lindsey Simbeye, Rosemarie MacDowell

**Absent:** See attached list.

Jason Hoppe, work group co-chair, called the meeting to order at 3:35 p.m.

A motion was made to approve the May 2021 work group meeting minutes. Motion passed.

#### **State Audit Overview – PDMP**

The audit was completed on June 21<sup>st</sup>. The audit recommended a review of the following: registration and registration requirements, considerations for leveraging the PDMP as an enforcement tool (including sharing of patient and prescriber data), enhancement of legislation related to registration enforcement mechanisms, ease of use, increased of integration, contract monitoring, and compliance mechanisms for pharmacies to correct submitted data. Some of the recommendations have been addressed in HB 1276. DORA is now in the process of prioritizing and implementing the recommendations.

[http://leg.colorado.gov/sites/default/files/documents/audits/1933p\\_colorado\\_prescription\\_drug\\_monitoring\\_program.pdf](http://leg.colorado.gov/sites/default/files/documents/audits/1933p_colorado_prescription_drug_monitoring_program.pdf)

#### **Comments/Questions:**

- Not enough data may have been collected in order to provide the end user perspective, i.e., pharmacists and prescribers.
- Family and patient perspectives were lacking.
- Will there be an opportunity for public feedback? Stakeholders provided input during legislation related to the PDMP upgrades and other changes.
- The audit lacks context.
- In the past, the PDMP was used as a tool for patient safety, not to punish providers. The objective pertained to clinical utility rather than enforcement. It is currently being used the way it was designed and legislated.
- The PDMP could have served as a law enforcement or payer-based tool (as it is in some states).

- CDPHE has only recently used the PDMP for population level surveillance.
- Any additional changes will require legislation.
- The PDMP topic could be addressed during the next legislative session; however, it would be best to offer some context beforehand.
- It would be useful to have more communication between the medical board and the pharmacy board.
- The PDMP does not sufficiently address the circumstances related to opioid use disorder as a result of chronic pain management for diseases such as cancer.
- There are occasions where legislative needs require collaboration between the pharmacy and medical boards, such as in the case of pharmacy protocols.
- The PDMP audit findings will be presented at all prescriber meetings by Dmitry and Ronne Hines.
- The PDMP auditors attended a recent El Paso County Coalition meeting to present the audit. The coalition is interested helping to educate providers.
- It will be important to educate providers about PDMP in general as well as the new statutory requirements in HB 21-1276. The Consortium Provider Education Work Group can assist.

DORA has agreed to all of the recommendations and is reviewing next steps, particularly those requiring legislation. Dmitry requested that the work group submit comments after DORA has had an opportunity to consider next steps.

**Legislation:**

HB 21-1276 was signed into law by Gov. Polis on June 26<sup>th</sup>.

<https://legiscan.com/CO/bill/HB1276/2021>

Questions were raised regarding how information in this bill would be clarified and disseminated to providers. Some sections of the bill that are contradictory. Dmitry said DORA summarizes bills and then disseminates the information to licensees by email. Websites and other boards are also updated. Any new requirements are addressed in town halls or other fora. Jose Esquibel said the Benzodiazepine Action Work Group has a particular interest in this bill and may invite a DORA representative to one of their work group meetings.

HB 21-1012 PDMP Expansion. <https://legiscan.com/CO/bill/HB1012/2021>

Dmitry suggested that a wider discussion could be held regarding this bill during an ad hoc meeting separate from the regularly scheduled PDMP Work Group meeting.

Carrie Paykoc provided a brief update. She indicated that Apriss could provide recommendations for legislation. She also spoke about leveraging Medicaid and Medicare funds to support infrastructure (Federal funds matching) and sharing recommendations.

<https://oehi.colorado.gov/colorado-health-it-roadmap>

<https://docs.google.com/document/d/1HuTvSySG05zXwbJqVpPEGzIqoZqkoUT0bccavNAzITM/edit?usp=sharing>

**PDMP Annual Report:**

The annual report has been submitted to the legislature. A link to the report will be posted on the DORA website.

**Adjournment and Next Meeting:**

The meeting adjourned at 4:19 p.m. The next meeting will be held on Thursday, September 9, 2021.

Attachment: Work group roster